Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors
19 déc. 2022 08h00 HE
|
Fortress Biotech, Inc.
MIAMI, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...
Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa
14 déc. 2022 08h00 HE
|
Fortress Biotech, Inc.
MIAMI, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”) (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”)...
Fortress Biotech to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference
06 déc. 2022 08h30 HE
|
Fortress Biotech, Inc.
MIAMI, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and...
Fortress Biotech Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
14 nov. 2022 16h01 HE
|
Fortress Biotech, Inc.
Net revenue for the nine months of 2022 increased 17.5% period-over-period to $59.3 million Cosibelimab BLA submission for metastatic and locally advanced cutaneous squamous cell carcinoma expected...
Fortress Biotech Announces Timing of Regular Monthly Dividend for October, November and December 2022 for its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
05 oct. 2022 08h30 HE
|
Fortress Biotech, Inc.
MIAMI, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on...
Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer
03 oct. 2022 08h00 HE
|
Fortress Biotech, Inc.
MIAMI, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”) (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”)...
Fortress Biotech to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
08 sept. 2022 08h30 HE
|
Fortress Biotech, Inc.
MIAMI, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress” or “the Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing...
Fortress Biotech Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
11 août 2022 16h30 HE
|
Fortress Biotech, Inc.
Net revenue for the first half of 2022 increased 45.5% period-over-period to $42.8 million Positive results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell...
Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver Transplantation
11 août 2022 08h00 HE
|
Fortress Biotech, Inc.
MIAMI, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...
Fortress Biotech Appoints David Jin as Chief Financial Officer
22 juil. 2022 08h00 HE
|
Fortress Biotech, Inc.
MIAMI, July 22, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and...